Skip to main content

David Gómez Andrés

-

Institutions of which they are part

Postdoctoral researcher
Pediatric Neurology
Vall Hebron Institut de Recerca
Doctor
Paediatric Neurology
Children's Hospital and Woman's Hospital

David Gómez Andrés

Institutions of which they are part

Postdoctoral researcher
Pediatric Neurology
Vall Hebron Institut de Recerca
Doctor
Paediatric Neurology
Children's Hospital and Woman's Hospital

-

-

Projects

Distrofia muscular congénita tipo 1A: inhibición de la fibrosis y corrección mediante edición génica

IP: Barquinero Mañez, Jordi
Collaborators: Costa Comellas, Laura, Munell Casadesus, Francina, Gómez Andrés, David, Piñera Moreno, Rocío
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI22/01027
Duration: 01/01/2023 - 31/12/2025

Neurologia infantil

IP: Macaya Ruíz, Alfons
Collaborators: Neurologia infantil, Ventura i Expósito, Laia, Perez Dueñas, Belen, Costa Comellas, Laura, Munell Casadesus, Francina, Raspall Chaure, Miquel, Toro Riera, Mireia del, Felipe Rucián, Ana, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Dougherty de Miguel, Lucy
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 0.01
Reference: 2021 SGR 01171
Duration: 01/01/2022 - 31/12/2024

Mejora del rendimiento diagnóstico en genes sarcoméricos de gran tamaño

IP: Munell Casadesus, Francina
Collaborators: Costa Comellas, Laura, Martinez Saez, Elena Antima, Avilés García, Maite, Gómez Andrés, David
Funding agency: Instituto de Salud Carlos III
Funding: 73205
Reference: AC19/00048
Duration: 01/01/2020 - 31/12/2023

Grups de recerca en Neurologia Pediatrica

IP: Macaya Ruíz, Alfons
Collaborators: Gómez Andrés, David
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 0.01
Reference: 2017SGR01710
Duration: 01/01/2017 - 31/12/2020

Related news

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.

Related professionals

Patricia Rubio Garrido

Patricia Rubio Garrido

Multidisciplinary Nursing Research Group
Read more
Mireia Arnedo Valero

Mireia Arnedo Valero

Administration and Management
Read more
Judith Sacanell Lacasa

Judith Sacanell Lacasa

Shock, Organ Dysfunction and Resuscitation
Read more
Sandra  Peiro Sales

Sandra Peiro Sales

Main researcher
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.